LUNIRI will present scientific data at the ERA-EDTA meeting in Vienna: May 21, 2016. Session CME 9: Rheumatology for Nephrologists. Title of the talk: "The topoisomerase I inhibitor irinotecan as a new treatment option for lupus nephritis?", 13.15-16.30 HALL E
First patient with refractory lupus nephritis treated with irinotecan
Refractory mixed proliferative and membranous lupus nephritis treated with the topoisomerase I inhibitor irinotecan as add-on therapy
New Research Funding for LUNIRI
Steffen Frese, the founder of LUNIRI, received new research funding from the German Research Foundation. http://gepris.dfg.de/gepris/projekt/317392477?language=en
Research will be conducted at the German Rheumatism Research Centre in Berlin, Germany.
Berlin Marathon 2017
LUNIRI in the News
New scientific data published in Arthritis Research & Therapy
Cancelation of credit card payment
Scientific presentation at the 53rd ERA-EDTA congress in Vienna 2016
Scientific presentation at the ISN Nexus Meeting in Berlin
LUNIRI will present scientific data at the ISN Nexus meeting in Berlin at Saturday 16 April 2016 17.00-17.25 Melia Hotel, room Barcelona. Title of the talk:
Irinotecan, an upcoming treatment option for lupus nephritis?
Vote to help establish a new treatment for systemic lupus erythematosus.
Berlin radio will donate 50.000 Euro for non-profit organizations. And without funding LUNIRI will not survive after 2016. Therefore, vote for LUNIRI at https://50000.brf914.de/61F4S. Repeated voting one day after another is possible. If you don’t mind, forward this message to your friends and colleagues with SLE. Thanks for your support.